Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
Journal of Clinical Medicine · 06.03.2025 · 14 (5) · 1782
DOI: 10.3390/jcm14051782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.03.2025. Verfasst von Migang Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) has been reported to improve survival in patients with peritoneal carcinomatosis. This study aimed to investigate the morbidity and mortality rates of CRS with HIPEC in patients with ovarian cancers.
Methods
We retrospectively reviewed the medical records of patients who underwent CRS with HIPEC for ovarian cancer from January 2013 to July 2021 at two tertiary institutions. The morbidities and mortalities that occurred within 30 days after HIPEC and the clinical and operative factors related to morbidities were investigated.
Results
A total of 155 procedures in 151 patients were included in this study. The median age was 55 years and the median score of the peritoneal carcinomatosis index was eight points. Morbidities of grade ≥3 within 30 days of HIPEC occurred in 18 patients (11.6%). The most common severe morbidity was wound infection (3.2%), followed by pleural effusion (1.9%) and postoperative hemorrhage (1.9%). Within the 30-day postoperative period, there were no reported mortality cases. There were statistical differences in age, length of stay, peritoneal carcinomatosis index, bowel resection, operation time, and completeness of cytoreduction between the patients and severe morbidity. However, in the multivariate logistic analysis, none of the factors showed a statistically significant relationship with the occurrence of severe morbidity.
Conclusions
The morbidity and mortality rates of CRS with HIPEC in gynecologic cancer patients were relatively low compared to those in previous reports. Further studies about the possible risk factors are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea.
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
ORCID-Profile: Migang Kim, Yong Jae Lee, Ki Eun Seon, Min Chul Choi, Jung-Yun Lee
Zitieren
APA
Kim, M., Lee, Y. J., Seon, K. E., Kim, S., Lee, C., Park, H., Choi, M. C., & Lee, J. Y. (2025). Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Medicine, 14(5), 1782. https://doi.org/10.3390/jcm14051782
Vancouver
Kim M, Lee YJ, Seon KE, Kim S, Lee C, Park H, et al. Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Medicine. 2025;14(5):1782. doi:10.3390/jcm14051782
BibTeX
@article{Kim2025,
author = {Kim, Migang and Lee, Yong Jae and Seon, Ki Eun and Kim, Sunghoon and Lee, Chan and Park, Hyun and Choi, Min Chul and Lee, Jung-Yun},
title = {Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {5},
pages = {1782},
doi = {10.3390/jcm14051782}
}
EUVIMED